Naturally Splendid (TSXV:NSP) will be presenting at FOODEX Japan 2017 from March 7 to March 10. FOODEX Japan is the largest annual food and beverage trade show in Asia, and has been a highly successful trade event since its debut in 1976, serving Japan’s $585-billion food market and additional significant Asian markets. Over 76,500 professional visitors attended FOODEX 2016, including over 9,000 from Korea, Taiwan, China, Thailand and Hong Kong.
Naturally Splendid will be presenting a wide range of products at FOODEX Japan, including debuting its new division, Natera CBD (cannabidiol).
-NATERAtrademark CBD (Cannabidiol) – featuring a product line of capsules formulated with CBD.
The capsules are 15 or 25 mg of Full Spectrum Hemp Extract with NO-THC and are manufactured using a BioAvailable Proprietary Formulation for Full & Fast Absorption.
-NATERAtrademark HEMP FOODS – retail division which includes; seeds, proteins and oils
-NATERAtrademark INGREDIENTS – bulk division which also includes HempOmega{A ™}
Naturally Splendid President Mr. J. Craig Goodwin states, “We have been working diligently in developing a solid business strategy for CBD based products. The regulatory environment regarding CBD products continues to evolve, creating opportunities for Naturally Splendid in the region. For our initial CBD product, the Company has negotiated an exclusive sales agreement for Japan with an established manufacturer of exceptional quality CBD capsules. We are currently evaluating and finalizing several other CBD related products, some of which may be included in the debut of NATERA trademark CBD in Japan”.
Naturally Splendid CEO Mr. Dave Eto states, “As part of our Strategic Plan, we have restructured our branding under the NATERA{A ™} banner; thus, we will build a stronger presence in various multiple geographical territories. I am particularly encouraged with our new division NATERAtrademark CBD and the emerging opportunities it brings. I will personally be attending JAPAN TRADEX with Craig Goodwin and we will be investigating multiple opportunities for NATERAtrademark CBD and HempOmega{A ™}.”
Naturally Splendid will be presenting with Eat Real Snack Foods at JAPAN FOODEX who are participating as Canadian Delegates in the Canadian Pavilion. Naturally Splendid recently completed an acquisition of a comprehensive state-of{A –}the-art packaging line from Eat Real Snack Foods and continues to develop business opportunities between the Companies. JAPAN FOODEX is indicative of the potential synergies between the companies.
According to Agriculture and Agri Food Canada;
– Japanese packaged food sales were valued at US$158 billion in 2015, and are anticipated to reach US$164.2 billion by 2020.
– Japanese consumers are renowned for placing enormous importance on consuming food that is both safe and of high-quality, and they perceive Canada as a country that produces food with these characteristics. Japan is a trendsetter in many areas, and it can be a very useful gateway to other markets within Asia.
Stock Options Granted
Naturally Splendid has granted 60,000 stock options to a consultant. The options were granted for a period of five (5) years, expiring on February 13, 2022. The stock options will vest over two years and each stock option will allow the holder to purchase a common share of Naturally Splendid at an exercise price of $0.35.
About Naturally Splendid Enterprises Ltd.
Naturally Splendid is a multifaceted biotechnology company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.
Click here to connect with Naturally Splendid (TSXV:NSP) to receive an Investor Presentation.

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less